Biotech Values

[DewDiligence]

DVAX – The HBV vaccine, Heplisav, met its primary endpoint in a phase-3 study. However, Heplisav continues to be on clinical hold by the FDA due to the possibility of a rare side effect (#msg-27721992).

http://biz.yahoo.com/bw/080805/20080805006540.html

DVAX’s market cap is less than the company’s cash on hand.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”